A case of hypophosphatemic osteomalacia
β
Frances Milat; Phillip Wong; Peter J Fuller; Lillian Johnstone; Peter G Kerr; Ja
π
Article
π
2011
π
American Society for Bone and Mineral Research
π
English
β 65 KB
## Abstract Patients with Ξ²βthalassemia major require ironβchelation therapy to avoid the complication of iron overload. Until recently, deferoxamine (DFO) was the major iron chelator used in patients requiring chronic hypertransfusion therapy, but DFO required continuous subcutaneous therapy. The